

FOR IMMEDIATE RELEASE

**PluroGen Therapeutics, Inc. To Attend the European Wound Management Association (EWMA) Conference 2013, 15 to 17 May in Copenhagen, Denmark**

Norristown, PA, 12 April, 2013

PluroGen Therapeutics, Inc, an emerging leader in advanced wound care solutions, announced today that it will be attending the European Wound Management Association (EWMA) Conference to be held at the Bella Center in Copenhagen, Denmark, 15-17 May, 2013. PluroGen will be discussing and demonstrating its PluroGel<sup>®</sup> line of wound care products. Neal Koller, President and CEO of PluroGen and Kati Weiss, European Manager will be available throughout the conference for one-on-one meetings at the PluroGen Booth #C2-029, located in the Bella Conference Center. To set up a meeting during the show with a PluroGen representative, please email [europe@plurogen.com](mailto:europe@plurogen.com).

PluroGen has developed a portfolio of 3 synergistic and complementary patented technologies that are sharply focused to products for the burn, wound and skin care markets. PluroGel PSSD, one of PluroGen's line of patented surfactant burn and wound products is being used in burn and wound centers across Europe. "Our team is very excited about returning to the EWMA Conference. We had such tremendous response last year in Vienna that we wanted to continue our discussions and share PluroGel's wound care success stories with conference attendees." said Neal Koller, President and CEO of PluroGen. "We want to continue to tell our story about how our new PluroGel surfactant products can help physicians make great strides in their day to day wound care challenges."

**About PluroGen Therapeutics, Inc.**

PluroGen Therapeutics, Inc. is a burn, wound, and skin care company providing clinically advanced and superior products from its multiple, patent-protected technology platforms. The Company's primary platform is its core PluroGel<sup>®</sup> surfactant technology which provides products with paradigm-shifting, superior and differentiated Core, Bio-Physical, and Performance Functions resulting in unique and advantaged Multi-Function products. Products based on PluroGel<sup>®</sup> are University developed and are in routine use, having shown superior results on more than 12,000 patients in two different patient populations- severe burns and non-healing wounds. PluroGen's three technology platforms are configured to deliver a variety of medicinal and beneficial compounds covering the six key areas of treatment in tissue management and healing: 1. Cleansing; 2. Anti-Infection; 3. Reduced Pain; 4. Anti-Inflammation; 5. Tissue salvage; 6. Tissue regeneration.

PluroGen has a strong new product pipeline and its senior management, operations team, boards and principal investigators are all recognized global commercial and clinical leaders in PluroGen's target markets of burn and wound care.

More information can be found on the company web site at <http://plurogen.com>.

For PluroGen Investor Information please call +1 (610) 539-3670.

**About European Wound Management Association**

The European Wound Management Association (EWMA) was founded in 1991, and the association works to promote the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. Over 2000 experts, practitioners and company representatives working with wound healing and wound management will be in attendance. More than 2900 participants and exhibitors joined the EWMA 2012 conference in Vienna. We look forward to seeing you in 2013 in Copenhagen. Additional information on the conference can be found at <http://www.ewma2013.org>.

**Safe Harbor Statement:**

The statements in the press release that relate to PluroGen's (the company) expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.